Reuters logo
BRIEF-Newlink Genetics reports positive Phase 1B data for co's IDO pathway inhibitor
June 23, 2017 / 11:16 AM / 3 months ago

BRIEF-Newlink Genetics reports positive Phase 1B data for co's IDO pathway inhibitor

June 23 (Reuters) - Newlink Genetics Corp:

* Positive phase 1b data for Newlink Genetics’ IDO pathway inhibitor, indoximod, in combination with chemotherapy for patients with newly diagnosed acute myeloid leukemia (aml) presented at the European Hematologic Association (eha) congress in Madrid, Spain Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below